Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7552930 | 1.00 | LTB4R (0.47) | LTB4RLTB4R2MTNR1AMTNR1BNFKB1 | |
| SCHEMBL7557806 | 1.00 | LTB4R (0.47) | LTB4RLTB4R2MTNR1AMTNR1BNFKB1 | |
| Hydrochloric Acid SCHEMBL8858324 | 0.99 | LTB4R (0.47) | LTB4RLTB4R2MTNR1AMTNR1BNFKB1 | |
| SCHEMBL8858322 | 0.87 | MTNR1A (0.45) | MTNR1AMTNR1BNFKB1NFKB2RELA | |
| SCHEMBL9371775 | 0.85 | SMN1; SMN2 (0.49) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL13534458 | 0.83 | MTNR1A (0.42) | MTNR1AMTNR1B | |
| SCHEMBL7314503 | 0.83 | TDP1 (0.56) | LTB4RLTB4R2MTNR1AMTNR1BCYP1A2 | |
| SCHEMBL23911581 | 0.81 | NFKB1 (0.41) | LTB4RLTB4R2NFKB1NFKB2RELA | |
| SCHEMBL9379902 | 0.81 | MTNR1A (0.45) | MTNR1AMTNR1BNFKB1NFKB2RELA | |
| SCHEMBL8969478 | 0.79 | TAAR1 (0.51) | NFKB1NFKB2RELACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177616-A1 | Use of chromans | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-28 | — | — | US | disclosed |
| US-5696137-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5696136-A | TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
| US-5693653-A | ADMINISTERING AN ANTIDEPRESSANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5585392-A | TREATING OR PREVENTING STROKES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | disclosed |
| US-5571909-A | ANTIBIOTICS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1996-11-05 | — | — | US | disclosed |
| US-5545643-A | USEFUL FOR TREATING DISEASES OF CENTRAL NERVOUS SYSTEM | BAYER AKTIENGESELLSCHAFT (DE) | 1996-08-13 | — | — | US | disclosed |
| US-5506246-A | Method for treating depression using substituted aminomethyltetralins and their heterocyclic analogues | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-09 | — | — | US | disclosed |
| US-5492918-A | Use of substituted chromans, some of which are known, as medicaments, new active compounds and processes for their preparation | BAYER AKTIENGESELLSCHAFT (DE) | 1996-02-20 | — | — | US | disclosed |
| EP-0628310-A1 | Use of partially known substituted chromanes as medicine, new products and process for their preparation | BAYER AG (DE) | 1994-12-14 | — | — | EP | disclosed |
| US-5371094-A | Azaheterocyclylmethyl-chromans for treating axiety | BAYER AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| EP-0352613-B1 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1994-04-20 | — | — | EP | disclosed |
| US-5300523-A | Binding serotonin receptors, treating nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1994-04-05 | — | — | US | disclosed |
| US-5137901-A | For binding 5-HT 1 receptors; treating central nervous system disorders | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-11 | — | — | US | disclosed |
| EP-0352613-A2 | Substituted amino methyl tetralines, and their heterocyclic analogous compounds | BAYER AG (DE) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177616-A1 | Use of chromans | SNCA, PARK7, COMT | LTB4R 4157/4885LTB4R2 4276/4885MTNR1A 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.